This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Actelion Pharmaceuticals Ltd.
Drug Names(s): Stayveer
Description: Tracleer is a competitive antagonist at endothelin receptor types ETA and ETB. It has a slightly higher affinity for ETA receptorsthan for ETB receptors. Endothelin is a small peptide hormone that is believed to play a critical role in the control of blood flow and cell growth. Tracleer was the first approved oral treatment for pulmonary hypertension (PAH) patients.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Actelion and Genentech
In 2000, Actelion partnered with Genentech to develop and promote Tracleer in the U.S. Under the terms of the agreement, both Actelion and Genentech will be involved in the marketing and promotion of Tracleer in the United States, with Actelion taking the lead in the development efforts and commercialization of Tracleer. Payments from Genentech include an up-front fee of $35 million (US dollars) plus additional payments contingent on the achievement of future milestones.
Actelion and Roche
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
Actelion and...See full deal structure in Biomedtracker
Partners: Roche Holding AG Biotoscana International
Additional information available to subscribers only: